Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory ...

The phase III studies STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) are evaluating the efficacy and safety of povorcitinib in adult patients with moderate to severe HS. Both studies include a ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...